ClinicalTrials.gg
RecruitingNCT06024187Updated Feb 13, 2025

Cold Dissection Versus Electrocautery Dissection in Endoscopic Nipple-Sparing Mastectomy and Immediate Implant-Based Reconstruction: A Randomized Controlled Trial

An interventional study of Cold dissection and Electrocautery Dissection in Breast Neoplasms, sponsored by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University. Recruiting at 1 site in China. Open to female participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-02-13.

Sponsored by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Nov 2022; still recruiting 3 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
566
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 101 studies in Breast Neoplasms by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University — 59 open to participants now, 67 under way, 18 of them phase 3. Breast Neoplasms · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University.

Planned enrollment
4th of 72
566 · median 165
Started
2022
with 10 others
No phase
20 of 101
13 open now
Primary completion
2026-12
later than 24 of 66 live
Registered
42nd of 101
by date

Among the 101 studies in Breast Neoplasms by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, this one is the 4th largest by planned enrollment of the 72 interventional ones that give a count, is one of 11 that started in 2022, is one of 20 with no phase, reaches primary completion later than 24 of the 66 other live ones, and was the 42nd registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

59 of the 101 studies in Breast Neoplasms by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University are open now, in 1 country. Recruiting first, the newest first:

54 more — sign in →

By country, each count listing its studies:

All 59 open studies →

Where they have run

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years to 75 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 101 studies in Breast Neoplasms by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, or all of them as a file.
02

Study summary

The purpose of this study is to analyze whether cold dissection can decrease the rate of ischemia necrosis and other complications and then increase the aesthetic outcomes compared to electrocautery. The purpose of this study is to analyze whether cold dissection can decrease the rate of ischemia necrosis and other complications and then increase the aesthetic outcomes compared to electrocautery.

Read the detailed description

Breast cancer is the most common cancer among women in the world. Although breast-conserving surgery is a viable option for patients, mastectomy remains the choice of treatment. Despite oncologic and surgical safety of nipple-sparing mastectomy(NSM) with immediate breast reconstruction(IBR) were amply demonstrated, a number of acute and late complications can occur. Surgical technique may play a role in the postoperative outcomes of mastectomy skin flap.Previous studies suggest that cold dissection with scissors or scalpel, may lead to decreasing blood loss and rates of skin necrosis, compared to electrocautery. A retrospective study by Troy Ng demonstrated that the use of cold dissection is likely to decrease the rate of partial-thickness necrosis (13.0%→33.3%, p=0.01) and full-thickness necrosis (1.3%→12.8%, p=0.02). The purpose of this study is to analyze whether cold dissection can decrease the rate of ischemia necrosis and other complications and then increase the aesthetic outcomes compared to electrocautery.

03

Conditions studied

  • Breast Neoplasms

Keywords

  • Endoscopy
  • Mastectomy
  • Breast Implants
  • Necrosis
  • Dissection
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Tumor smaller than 5 cm
  • No evidence of NAC, skin or chest wall invasion.
  • The general inclusion criteria or pre-requisite for nipple sparing mastectomy apply to E-NSM as well.

Exclusion criteria

Exclusion Criteria:

  • Patients with apparent NAC involvement, chest wall or skin invasion, inflammatory breast cancer, locally advanced breast cancer or severe comorbid conditions or poor performance status assessed by the primary physicians, such as heart disease, renal failure, liver dysfunction, and poor performance status as assessed by the primary physicians.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
566 participants (estimated)

Study arms

  • Experimental
    Cold Dissection

    In this group, the septa between the skin flap and parenchyma was dissected using with scissors or scalpel

    Procedure: Cold dissection

  • Active comparator
    Electrocautery Dissection

    In this group, the septa between the skin flap and parenchyma was dissected using with electrocautery

    Procedure: Electrocautery Dissection

Interventions

  • ProcedureCold dissection

    The subcutaneous flap dissection was performed with a scissor in this group. The boundary of mastectomy flap was defined as the edge of clavicle superiorly, the edge of sternum medially, the edge of inframammary fold inferiorly, and the edge of the latissimus dorsi laterally. Our tumescent technique utilizes a solution made by mixing 0.2ml of epinephrine with 250 ml of 0.9% Sodium Chloride solution to create a 1‰ ratio. 150ml to 150ml of the solution was injected into the subcutaneous tissue of the operated breast with a 20-gauge spinal needle to establish a bloodless plane. The septa between the skin flap and parenchyma then was dissected using a scissor.

  • ProcedureElectrocautery Dissection

    The subcutaneous flap dissection was performed with electrocautery in this group. The boundary of mastectomy flap was defined as the edge of clavicle superiorly, the edge of sternum medially, the edge of inframammary fold inferiorly, and the edge of the latissimus dorsi laterally.

06

What researchers measure

Primary outcomes

  1. Necrosis complications within one month post operation

    Necrosis complications included nipple-areolar complex (NAC) and skin flap necrosis. NAC/skin flap necrosis could present as minor superficial epidermolysis requiring local wound care only, or full-thickness necrosis with any exposure of acellular dermal matrix, muscle, implant, or with full-thickness eschar that required surgical reoperation of debridement and repair.

    Time frame: Within one month post operation

Secondary outcomes

  1. Necrotic complications within 1 year post operation

    Time frame: Within 1 year post operation

  2. Surgical-site infection rate(SSI)

    the incidence of surgical-site infection will be compared between two groups

    Time frame: within one year post operation

  3. The incidence of postoperative complications

    the incidence of seroma, hematoma, blister, implant capsular contracture, and implant loss will be compared between two groups

    Time frame: within one year post operation

  4. Cosmetic outcomes evaluated by 5-point Likert Scale

    Evaluated by patients and five surgeons. In this scale, breast fullness; nipple-areola complex, shape, and contour; scar appearance, size, and fullness; and overall breast appearance will be assessed.

    Time frame: Evaluated pre-operation, at the first month, at 2 months, 3 months, 6 months and 12 months.

  5. Patient-reported outcomes (as measured using the BREAST-Q score)

    The modules included Satisfaction with Breasts, Psychosocial Wellbeing, Sexual Wellbeing, and Physical Wellbeing Chest, Surgeon, Medical Staff, Office Staff.

    Time frame: Evaluated pre-operation, at the first month, at 2 months, 3 months, 6 months and 12 months.

  6. Postoperative pain

    Pain was assessed using a visual analogue scale(VAS), where 0 = no pain and 10 = worst possible pain.

    Time frame: Evaluated at the first day, second day, third day and the first week, second week.

  7. Total operation time

    Defined as the time calculated from the skin incision to the end of wound closure

    Time frame: Immediate post operation

  8. Intraoperative estimated blood loss

    Blood loss (ml) during operation was compared between groups

    Time frame: Immediate post operation

  9. Drain volume

    Total drain volume(ml) within three days post operation

    Time frame: within three days post operation

  10. Duration of hospital stay post operation

    Duration of hospital stay post operation(d) will be compared between two group.

    Time frame: Within 2 weeks of operation.

  11. Weight of the excised gland

    Mean mastectomy weight of patients will be compared between two groups.

    Time frame: Immediate post operation

  12. Size of implant

    Size of implant will be compared between two groups.

    Time frame: Immediate post operation

07

Study locations

1 of 1 sites recruiting
  • Shicheng Su
    Guangzhou, Guangdong 510120, China
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2022 (actual). Primary completion is estimated for Dec 2026, 49 months after the start.

Of 2,673 non-industry interventional studies with no phase under Breast Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 66. This study's planned 49 months is above that.

Counting every sponsor, half of 2,783 studies reached it within 33 months; a quarter within 15 and three quarters within 66.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 30, 2022
First posted
Sep 6, 2023
StartActual
Nov 23, 2022
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Feb 13, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 13, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06024187
Responsible party
Sponsor
First posted
Sep 6, 2023
Start date
Nov 23, 2022
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Feb 13, 2025

Study contacts

Shicheng Su
Contact
sushch@mail.sysu.edu.cn
+86 13631304227
Shicheng Su
principal investigator · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion